Gland Pharma Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/tabm5cmwhfczd8zgkbpq8aas.pdf

Key Takeaways


Supply Chain Disruptions

Srinivas Sadu: "Being the market is so volatile and the supplies are not yet 100% in line with our plan, it's very difficult to estimate the near term growth and difficult to comment on future growth or business guidance for short tenure."

US Market: Volume Pressure & Competitive Cycle

Srinivas Sadu: "We have to see whether the competition will stay intact, and how long can they sustain with this pricing what they're offering in the market. Because this is a cycle, we are in that space where we have seen that few years ago, where a lot of companies launched till the capacities get filled up and then they start exiting the market."

Margin Walk

Ravi Shekhar Mitra: "Once the revenue start coming, biosimilar Shamirpet facility, that would negate."

CDMO & Biosimilar Build-Out


Geographic & Product Diversification

Srinivas Sadu: "Once in five, six years where we have to consolidate the business, I think we're using that now. But from opportunity... we are pretty confident on the growth in the future because the opportunities are there."

Guidance & Commitments

CommitmentSpecificsTimeline
Heparin stopper normalizationSome stoppers expected in November; full normalization through existing and newly qualified suppliersQ1 next calendar year
US volume recoveryVolume degrowth should start recovering as prior pipeline inventory gets used upThis quarter or next quarter
US launches~25 SKU launches planned (9 this quarter, 16 next quarter)Next two quarters
China approvalsTwo products expected approval (one this quarter, one next quarter); six more next yearBy end of this year / next year
China filingsSix additional filings plannedFY24
Biosimilar CDMO revenue startBusiness will start for sure, but may not cover 100% of costs initiallyCalendar year 2023
EBITDA margin run-rateExcluding one-offs, should be around 30.5-31% on a quarterly basisOngoing quarterly basis
CAPEX spendOn track to spend ₹300-350 croreBy FY23 year-end
Complex filingsExpect another two complex filingsDuring current fiscal

Key Metrics

MetricQ2 FY23
Revenue from operations₹1,044.4 cr, down 3% YoY from ₹1,080.5 cr, up 22% QoQ
H1 FY23 revenue from operations₹1,901.3 cr, down 15% YoY
EBITDA₹362.5 cr, down 15% YoY from ₹427.8 cr
EBITDA margin33%, compared to 38% in Q2 FY22
EBITDA margin excluding other income28.5%, or ~30.5% adjusted for one-time items
PAT₹241.2 cr, down 20% YoY from ₹302.1 cr
PAT margin22%
Gross marginStable YoY in Q2 and H1; QoQ decline due to geography and product mix
R&D expenditure (excl. capital R&D)3.8% of revenue, ₹39.4 cr, up 9% YoY from ₹36.2 cr (3.3% of revenue)
Cash flow from operations (quarter)₹62.7 cr
Cash flow from operations (H1 FY23)₹395.6 cr
Total cash and bank balances₹3,820 cr as of September 2022
CAPEX incurred (H1 FY23)₹82.5 cr
Core markets revenue share72% of revenue, up from 67% in Q2 FY22
Rest of World revenue share21% of revenue, same as Q2 FY22
India revenue share7% of revenue
US profit share7% for the quarter; 8% for H1 FY23 and H1 FY22
Revenue from new launches~3% of revenue
Product SKUs launched6 during the quarter
ANDA filings completed6 during the quarter
Total ANDA filings in the US322 as of 30th September 2022
Total product registrations globally1,586 as of 30th September 2022
US volumesDegrowth of 7%–8%
Rest of World gross margin25%, down from 35% in Q2 FY22
Canada contribution margin65%, down from ~88%
Heparin stopper-related sales loss~₹40–50 cr per quarter
CDMO non-revenue OPEX at EBITDA level₹15 cr for the quarter, plus ₹6–7 cr depreciation
One-time inventory write-off (biologic CDMO)~₹7–8 cr, ~0.7%–0.8% impact on gross margin
M&A cost~₹4 cr
Headcount added for biosimilar business~500 employees
Liquid vials capacity utilization85%–90%
Lyophilizer capacity utilization~80%
Average cash conversion cycle (H1 FY23)231 days, up from 198 days in H1 FY22
ROCE on ex-cash basis (H1 FY23, annualized)21%
Fixed assets turnover (H1 FY23)2.4x, down from 3.4x in H1 FY22
Effective tax rate~26% in Q2 and H1 FY23
China filings8 products filed; 2 approvals expected by end of CY22, 6 in CY23; 6 more filings planned in FY24
US SKU launches planned (next two quarters)~25 (9 in Q3, 16 in Q4); 20 launched in H1 FY23